Private Equity’s Emerging Interest in Autism Therapy Companies
Private equity investment in adolescent behavioral therapy has skyrocketed in recent years. Both investors with a track record for partnering with healthcare companies, as well as generalist funds, have come up to speed quickly with an interest in adolescent behavioral care. Numerous attributes of adolescent behavioral health companies align with private equity’s interests and experience, and recent M&A in the space suggests that market opportunities exist for the first-movers that can build large platforms for providing care nationwide.
Unknown to most individuals outside the profession, a highly specialized medical doctor exists within the realm of dermatology. Mohs surgeons play the part of both skin cancer surgeon and pathologist. Amazingly, in a country of approximately 320 million people, only 1,500 Mohs surgeons (American College of Mohs Surgery Fellowship trained) exist – making their unique skills and services rare and valuable. In layman’s terms, if Mohs surgeons were professional baseball players, they would be left-handed knuckleballers.
Private Equity-Backed Specialty Physician Platforms – Where do we go from here?
Over the past five years there has been a tremendous amount of private equity investment in specialty physician groups. Seemingly every middle market sponsor with an interest in healthcare has sought or bought a specialty physician practice, be it in dermatology, dental, or ophthalmology, with the intent of building a platform by executing a “roll-up” strategy. Notably, many of these investments, through prodigious amounts of work, have succeeded in creating regional platforms of scale, with strong leadership and meaningful infrastructure.
How Efforts to Reduce the Cost of Healthcare in the U.S. May Impact Patients, Payors, and Providers
$3,300,000,000,000: That is how much the U.S. spent on healthcare in 2016, and that number is only rising. The price of medical care has grown over 2,000% since 1960—compared to just over 500% for the consumer price index as a whole. In total, Americans’ health care tab represented approximately 18% of GDP, while the OECD average healthcare spending amounted to only 10% of GDP.
Increasing Prevalence of Surgeries Performed in an ASC Setting . . . continued
As mentioned last week, in this blog we’ll look at specialties that are well positioned to transition some patient cases to an ASC setting, and what factors, including reimbursement decisions, patient outcomes, and technology are a fit with ASCs.
Increasing Prevalence of Surgeries Performed in an ASC Setting
It is increasingly common to hear the term (“ASC”), or ambulatory surgery center, in discussions among investors in the healthcare industry. ASCs, often owned by the physicians who practice in them, can provide a cost-effective alternative to care delivery in a hospital setting, drive better patient outcomes, and allow physician owners to capture more of the economics associated with the delivery of patient care.
Examining the Potential Impact of New ACS Screening Guidelines on Gastroenterologists
On Wednesday, May 30, 2018, the American Cancer Society (“ACS”) announced a major change to the recommended age for beginning colorectal cancer screening. Previously, the organization recommended that those at average risk of colorectal cancer begin regular screening at age 50. However, prompted by a 2017 study led by ACS researchers and published in the Journal of the National Cancer Institute, which found that new cases of colon cancer and rectal cancer are occurring at an increasing rate among young and middle-aged adults, the ACS is providing guidance to lower the recommended age for beginning screening to 45.
Lifesaving Therapies and Eye-catching Returns in the CRO Market
On average, pharmaceutical companies spend $2.6 billion over the course of 10 years to develop a single new drug. That equates to over $115 billion invested in the 46 novel drugs approved by the FDA in 2017—not to mention the 90%+ of therapeutics that never advance further than clinical trials.
With such astronomic costs looming over the industry, it’s no surprise that pharma companies are doing whatever they can to make R&D processes as efficient as possible. The need to cut costs and optimize development has given birth to a number of ancillary industries, from specialized PR firms to outsourced drug manufacturers (“CMOs”). The value proposition is simple: provide the time and labor-intensive services necessary to take drugs across the finish line at a lower cost, while allowing pharmaceutical companies to focus on what they do best: developing lifesaving therapies.
Why Private Equity is Turning Its Attention to Gastroenterology
M&A activity between physician practices and private equity investors has evolved meaningfully over the last several years. Coming out of the Great Recession, investors pursued consolidation, administrative optimization, and networking improvements in specialties such as dentistry, dermatology, physical therapy, and anesthesiology. Today, having written the playbook for successful partnerships with physician practices, investors have begun identifying the next wave of attractive specialties in healthcare services to implement proven investment strategies.
The Benefits and Increasing Prevalence of Ambulatory Surgery Centers
The first Ambulatory Surgery Center (“ASC”) was established in the 1970s by two Phoenix, AZ-based physicians seeking to “provide timely, convenient, and comfortable surgical services” to patients.1 Today, as the healthcare industry collectively seeks to drive down costs, improve patient health outcomes and overall satisfaction, ASCs have become an increasingly common option for both outpatient and higher acuity surgical procedures.